chimerix
http://www.washingtonpost.com/news/post-nation/wp/...died-from-ebola/
aber die aktie will nach oben,denke ich.(sobald die märkte sich beruhigen)
Chimerix (CMRX) Provides Detailed Results From Phase 3 SUPPRESS Trial; to Close Phase 3 SUSTAIN and SURPASS Trials
http://www.streetinsider.com/Corporate+News//...eetings/11344156.html
Laden wird langsam interessant für ein Kauf...
ca. 224M MK
Chimerixs balance sheet at September 30, 2015 included $378.4 million of capital available to fund operations
Over the weekend, the company presented new, re-hashed results from the SUPRESS study, suggesting that patients on brincidofovir benefited more than those receiving a placebo, and that failure to follow study protocol might be the culprit behind the disappointment in December. Essentially, doctors may have mis-diagnosed and mis-treated patients in the study who presented with diarrhea, a known side effect of brincidofovir but also a symptom of Graft-vs-Host-Disease. Chimerix believes that corticosteroids, given to treat GVHD, may have contributed to the drugs failure. Study protocol called for interruption of the drug if diarrhea presented, and the median cumulative exposure to corticosteroids was 8-fold higher in subjects on brincivofodir than those on placebo. Steroids, not drug ineffectiveness, might be to blame for brincidofovirs inability to reduce the risk of infection at 24 weeks
The company ended the year with just under $350 million in cash and equivalents. On Monday, the companys market capitalization stood at $230 million.
http://www.forbes.com/sites/jakeking/2016/02/22/...tech/#43b1e757254b
Chimerix Inc. Is Roaring Higher Again -- Here's Why
http://www.fool.com/investing/general/2016/01/20/...er-heres-why.aspx
BK doorway? Brinci falters but still game as Chimerix explores varied pathways
http://www.bioworld.com/content/...himerix-explores-varied-pathways-0
Chimerix to Announce Fourth Quarter and Full Year 2015 Financial Results on February 29, 2016
http://ih.advfn.com/p.php?pid=nmona&article=70487722
Studie läuft noch....
Brincidofovir (CMX001) in the Treatment of Early Versus Late Adenovirus Infection
Estimated Primary Completion Date: December 2016
https://clinicaltrials.gov/ct2/show/NCT02087306
http://www.clinicalcollections.org/trials/...ew=view_timelinebyphases
die Pipeline gibts gerade gratis, denke der Markt hat heftig übertrieben gestern..
Ich denke auch, dass jetzt Einkaufskurs bestehen. Allein wenn man bedenkt, dass der Cashbestand höher ist als die aktuelle MK, der Freefloat sehr gering ist und fast nurinstitutionelle/Fonds investiert sind.
MARIO ERNEST 125,000 $7.09 $886,612.00 262,63
Machado Clarence Patrick 10,000 $7.08 $70,846.00 10,000
http://www.insidercow.com/
Chimerix Following Lowered Expectations
http://www.benzinga.com/analyst-ratings/...ollowing-lowered-expectati